Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir

Detalhes bibliográficos
Autor(a) principal: GASCON,Maria Rita Polo
Data de Publicação: 2020
Outros Autores: BENUTE,Glaucia Rosana Guerra, MACEDO,Elizeu Coutinho, CAPITÃO,Claudio Garcia, VIDAL,José Ernesto, SMID,Jerusa, MARCUSSO,Rosa Maria Nascimento, LUCIA,Mara Cristina Souza de, PENALVA-DE-OLIVEIRA,Augusto Cesar, DIAMENT,Decio
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000600342
Resumo: ABSTRACT Background: Hepatitis C can be defined as an infectious disease that develops an inflammatory activity, which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression. Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir. Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Fifty-eight patients under clinical follow-up were evaluated at the Emílio Ribas Infectology Institute, in São Paulo, Brazil. The following instruments were used: sociodemographic questionnaire, Lawton’s Scale, Beck’s Depression Inventory, and a battery of neuropsychological tests that evaluated: intellectual function, memory, attention, executive function, and motor and processing speed). For statistical analysis, the analyses described (mean, frequency, and standard deviation), chi-square, and ANOVA were used. Results: Most of the participants were male (n=30, 51.7%), with a mean of 58.23±8.79 years, mean schooling of 9.75±4.43 years. Comparing the results of neuropsychological evaluations (before, just after completion of drugs, and six months), a significant improvement was observed in relation to the acquisition of new knowledge (p=0.03), late visual memory (p=0.01), and tendency towards alternate attention (p=0.07). Conclusion: The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.
id ABNEURO-1_7df6f329cd2bcf2516306c0f7bde4418
oai_identifier_str oai:scielo:S0004-282X2020000600342
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or DaclatasvirHepatitis CCognitive DisordersCombined Modality TherapyABSTRACT Background: Hepatitis C can be defined as an infectious disease that develops an inflammatory activity, which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression. Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir. Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Fifty-eight patients under clinical follow-up were evaluated at the Emílio Ribas Infectology Institute, in São Paulo, Brazil. The following instruments were used: sociodemographic questionnaire, Lawton’s Scale, Beck’s Depression Inventory, and a battery of neuropsychological tests that evaluated: intellectual function, memory, attention, executive function, and motor and processing speed). For statistical analysis, the analyses described (mean, frequency, and standard deviation), chi-square, and ANOVA were used. Results: Most of the participants were male (n=30, 51.7%), with a mean of 58.23±8.79 years, mean schooling of 9.75±4.43 years. Comparing the results of neuropsychological evaluations (before, just after completion of drugs, and six months), a significant improvement was observed in relation to the acquisition of new knowledge (p=0.03), late visual memory (p=0.01), and tendency towards alternate attention (p=0.07). Conclusion: The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.Academia Brasileira de Neurologia - ABNEURO2020-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000600342Arquivos de Neuro-Psiquiatria v.78 n.6 2020reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/0004-282x20200022info:eu-repo/semantics/openAccessGASCON,Maria Rita PoloBENUTE,Glaucia Rosana GuerraMACEDO,Elizeu CoutinhoCAPITÃO,Claudio GarciaVIDAL,José ErnestoSMID,JerusaMARCUSSO,Rosa Maria NascimentoLUCIA,Mara Cristina Souza dePENALVA-DE-OLIVEIRA,Augusto CesarDIAMENT,Decioeng2020-06-23T00:00:00Zoai:scielo:S0004-282X2020000600342Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2020-06-23T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
title Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
spellingShingle Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
GASCON,Maria Rita Polo
Hepatitis C
Cognitive Disorders
Combined Modality Therapy
title_short Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
title_full Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
title_fullStr Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
title_full_unstemmed Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
title_sort Cognitive assessment in patients with Hepatitis C submitted to treatment with Sofosbuvir and Simeprevir or Daclatasvir
author GASCON,Maria Rita Polo
author_facet GASCON,Maria Rita Polo
BENUTE,Glaucia Rosana Guerra
MACEDO,Elizeu Coutinho
CAPITÃO,Claudio Garcia
VIDAL,José Ernesto
SMID,Jerusa
MARCUSSO,Rosa Maria Nascimento
LUCIA,Mara Cristina Souza de
PENALVA-DE-OLIVEIRA,Augusto Cesar
DIAMENT,Decio
author_role author
author2 BENUTE,Glaucia Rosana Guerra
MACEDO,Elizeu Coutinho
CAPITÃO,Claudio Garcia
VIDAL,José Ernesto
SMID,Jerusa
MARCUSSO,Rosa Maria Nascimento
LUCIA,Mara Cristina Souza de
PENALVA-DE-OLIVEIRA,Augusto Cesar
DIAMENT,Decio
author2_role author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv GASCON,Maria Rita Polo
BENUTE,Glaucia Rosana Guerra
MACEDO,Elizeu Coutinho
CAPITÃO,Claudio Garcia
VIDAL,José Ernesto
SMID,Jerusa
MARCUSSO,Rosa Maria Nascimento
LUCIA,Mara Cristina Souza de
PENALVA-DE-OLIVEIRA,Augusto Cesar
DIAMENT,Decio
dc.subject.por.fl_str_mv Hepatitis C
Cognitive Disorders
Combined Modality Therapy
topic Hepatitis C
Cognitive Disorders
Combined Modality Therapy
description ABSTRACT Background: Hepatitis C can be defined as an infectious disease that develops an inflammatory activity, which may cause an impairment in the central nervous system, may cause cognitive impairments and symptoms of depression. Objective: The objective of this study was to verify the cognitive performance of patients with chronic hepatitis C before and after treatment with simeprevir, sofosbuvir, and daclatasvir. Methods: A prospective study was carried out in three stages: before, right after treatment, and six months after. Fifty-eight patients under clinical follow-up were evaluated at the Emílio Ribas Infectology Institute, in São Paulo, Brazil. The following instruments were used: sociodemographic questionnaire, Lawton’s Scale, Beck’s Depression Inventory, and a battery of neuropsychological tests that evaluated: intellectual function, memory, attention, executive function, and motor and processing speed). For statistical analysis, the analyses described (mean, frequency, and standard deviation), chi-square, and ANOVA were used. Results: Most of the participants were male (n=30, 51.7%), with a mean of 58.23±8.79 years, mean schooling of 9.75±4.43 years. Comparing the results of neuropsychological evaluations (before, just after completion of drugs, and six months), a significant improvement was observed in relation to the acquisition of new knowledge (p=0.03), late visual memory (p=0.01), and tendency towards alternate attention (p=0.07). Conclusion: The treatment of the hepatitis C virus improved cognitive performance, especially in relation to memory.
publishDate 2020
dc.date.none.fl_str_mv 2020-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000600342
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2020000600342
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/0004-282x20200022
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.78 n.6 2020
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212786741706752